Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of lenalidomide (revlimid) in
combination with fludarabine and rituximab and to determine the highest dose of lenalidomide
that can safely be given in that combination. Lenalidomide is a drug that alters the immune
system and may also interfere with the the development of tiny blood vessels that help
support tumor growth. Lenalidomide is approved by the FDA for the treatment of two different
blood cancers called myelodysplastic syndrome and multiple myeloma. Lenalidomide has also
been studied in subjects with relapsed CLL. In this research study we are adding lenalidomide
to a well-established initial therapy for CLL/SLL.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Celgene Corporation Massachusetts General Hospital